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ABSTRACT: Noninvasive brain stimulation therapies are a 
promising field for the development of new protocols for the 
treatment of neuropsychiatric disorders. They are based on the 
stimulation of neural networks with the intent of modeling their 
synaptic activity to adequate levels. For this, it is necessary to 
precisely determine which networks are related to which brain 
functions, and the normal activation level of each of these 
networks, so that it is possible to direct the stimulation to the 
affected networks in order to induce the desired effects. These 
relationships are under intense investigation by the scientific 
community, and will contribute to the advancement of treatments 
by neurostimulation, with the emergence of increasingly accurate 
and effective protocols for different disorders. Currently, the 
most used techniques are Transcranial Direct Current Stimulation 
and Transcranial Magnetic Stimulation, with the most common 
applications being for treating Major Depressive Disorder. The 
advancement of research in this field may determine new target 
networks for stimulation in the treatment of other disorders, 
extending the application of these techniques and also our 
knowledge about brain functioning.
Keywords: Transcranial magnetic stimulation/standards; 
Implantable neuroestimulators; Neuropsychiatry; Nervous system 
diseases/therapy; Nervous system diseases/diagnosis.
RESUMO: As terapias biológicas não invasivas se apresentam 
como um campo promissor para o desenvolvimento de novos 
protocolos de tratamento de transtornos neuropsiquiátricos. 
Elas se baseiam na estimulação de redes neurais com intuito 
de modular sua atividade sináptica para níveis adequados. Para 
isso, é necessário a determinação precisa de quais redes estão 
relacionadas a quais funções cerebrais, e do nível de ativação 
normal de cada uma dessas redes, para que então seja possível 
direcionar a estimulação às redes afetadas a fim de induzir os 
efeitos desejados. Essas relações estão sob intensa investigação 
pela comunidade científica, e vão contribuir para o avanço 
dos tratamentos por neuroestimulação, com o surgimento de 
protocolos cada vez mais precisos e efetivos para diferentes 
transtornos. Atualmente, as técnicas mais utilizadas são a 
Estimulação Transcraniana por Corrente Contínua e a Estimulação 
Magnética Transcraniana, sendo a aplicação mais comum no 
tratamento do Transtorno Depressivo Maior. O avanço das 
pesquisas possivelmente determinará novas redes alvo para 
estimulação no tratamento de outros transtornos, estendendo a 
aplicação dessas técnicas e também do nosso conhecimento sobre 
o funcionamento cerebral.
Descritores: Estimulação magnética transcraniana/normas; 
Neuroestimuladores implantáveis; Neuropsiquiatria; Doenças do 
sistema nervoso/terapia; Doenças do sistema nervoso/diagnóstico.
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INTRODUCTION
The use of electric current as a form of treatment for neurological diseases dates back to Classical 
Antiquity, from the earliest documentation of medical 
practice. De Compositionie Medicamentorum, by 
Scribonius Largus, Roman Emperor Claudius’ physician, 
describes in detail a set of substances and recipes used by 
physicians of the time, and includes the use of electric rays 
for the treatment of headache and pain1,2. The etymology 
of the name of these electric rays in English, torpedo fish, 
is indicative of this origin: the word “torpedo” comes from 
the Latin “torpere” meaning numb.
The end of the eighteenth century was marked 
by the introduction of electrophysiology as a scientific 
discipline, beginning with Galvani’s findings in 1791 of 
the electrical excitability of the nerves3,4. This notion was 
expanded to the cerebral cortex with the works of Fritsch 
and Hitzig (1870)5, and other researchers of the time6-9, 
whose investigations produced conclusive evidence of the 
functional relationship of different brain regions through 
mapping with electrical stimuli10.
It was in the 1960s that scientists began investigating 
the modulation of neuronal activity by electrical current of 
a specific polarity. Bindman et al.11 showed that currents 
of 0.25 μA / mm² applied to the pia mater influenced the 
spontaneous activity and evoked potentials of neurons 
for hours after only minutes of electrical stimulation in 
rat brains. Purpura and McMurtry12 observed the same 
phenomenon in preparations of cats with currents of 20 μA 
/ mm² applied to the cerebral cortex. These experiments 
indicate that currents far below those required to evoke 
an action potential can alter the excitability of neurons, 
and create the theoretical basis for Transcranial Electrical 
Stimulation (TES).
In 1985, Barker et al.13 introduced the Transcranial 
Magnetic Stimulation (TMS), after solving the technical 
challenges associated with the creation of a pulse of 
magnetic field of sufficient intensity to penetrate the skull 
that could generate significant induced electrical currents 
in the brain circuits. They showed that a magnetic pulse 
applied to the motor cortex was able to cause muscle 
contraction generating a motor evoked potential (MEP) 
measured by electromyography (EMG).
Currently, neurostimulation is divided into a broad 
field of research with different applications. Unlike invasive 
therapies such as deep brain stimulation (DBS) and vagus 
nerve stimulation (VNS), or convulsive therapies such as 
electroconvulsive therapy (ECT) and magnetoconvulsive 
therapy (MCT), non-invasive brain stimulation therapies 
do not require sedation or anesthesia, whilst being able 
to modulate cortical activity and excitability of neurons 
through the intact skull. Its two main stimulation techniques 
are repetitive TMS (rTMS) and TES, the most widespread 
variant of which is Transcranial Direct Current Stimulation 
(tDCS), reintroduced in 2000 in its modern form[14].The 
aim of this chapter is to present, in a precise and succinct 
manner, the noninvasive stimulation therapies, rTMS and 
tDCS, and convulsive therapies, ECT and MCT. We will 
show the theoretical bases of each of them, explaining their 
mechanisms of functioning, as well as the emerging clinical 
applications for psychiatric disorders. Then, we will finish 
with a record of the main challenges faced and the future 
of these applications for psychiatry.
MECHANISMS OF ACTION
Transcranial Magnetic Stimulation (TMS)
TMS is based on the principle of induction of 
electric current in a circuit from a magnetic field as shown 
by Michael Faraday in 183215. It uses a coil in which an 
electric current is generated, which in turn generates a 
pulse of magnetic field, called a field coil. The generated 
field has a direction perpendicular to the field coils, and 
reaches an intensity similar to that produced by magnetic 
resonance (1.5-3T) devices, but for a short period of time 
(milliseconds)16. An electric field is induced in the brain 
circuits affected by the magnetic field. The induced field 
voltage may itself excite neurons, but induced currents are 
likely to be the most important for the observed effects17. 
In a homogeneous medium, the electric current is induced 
in circuits parallel to the field coil, which in the brain 
translates into directional currents mainly tangential to 
the surface of the skull. The higher current circuits will 
be those with a similar circumference to the coil, with the 
induced current decreasing as it approaches its center17. The 
ions dissolved in the cytosol of the neurons are displaced 
with the appearance of electric field induced by the field 
coil, this displacement being larger according to the field 
gradient generated within the neuronal element. It is of our 
interest that this field gradient passes through the neuronal 
membrane in order to induce current flow through it and 
subsequent activation of the neuron.
The excitatory and inhibitory effects generated by 
rTMS are similar to the effects of long-term potentiation 
(LTP) and long-term depression (LTD). LTP and LTD are 
two mechanisms of synaptic plasticity caused by biological 
phenomena that lead either to enhancement (LTP) or 
weakening (LTD) of the synapse, causing an increase or 
decrease of its efficiency. Among the observed similarities, 
we highlight: 1) rTMS induces effects that last beyond the 
stimulation period; 2) the temporal pattern of stimulation 
is important for determining the physiological effect; 3) 
the effects of rTMS depend on the previous state of the 
stimulated neural network; 4) rTMS is involved in the 
expression of brain-derived neurotrophic factor (BNDF) 
and c-fos, LTP-associated molecules; 5) the effects of rTMS 
are decreased by blocking N-methyl D-aspartate (NMDA) 
receptors; and 6) the effects of rTMS are associated with 
BDNF polymorphisms18,19.
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Transcranial Current Stimulation (tDCS)
TDCS is technically one of the simplest ways to 
stimulate the brain. It consists of the passage of electric 
current of low intensity through electrodes placed on 
the scalp in order to provoke alterations in the cerebral 
activity modifying the excitability of the affected regions. 
The injected current alters the resting membrane potential, 
hyperpolarizing it or depolarizing it, according to the 
direction of the current in relation to the axonal orientation, 
without, however, provoking activation11,12. In this sense, 
the technique is purely neuromodulatory, different from 
TMS which, in addition to being neuromodulatory, is also 
neurostimulatory2. In general, anodic currents increase 
neuronal excitability, demonstrated by an increase in 
MEP amplitude to TMS excitation, while cathodic 
currents decrease it. Stimulation lasting for a few seconds 
is sufficient to induce such excitability changes, which 
however do not last beyond the stimulation period20. An 
effective modulation of the neuronal activity that lasts for 
at least one hour requires a stimulation of minutes21.
The long-term effects of tDCS are probably related to 
several different mechanisms. Pharmacologically, evidence 
indicates that these effects are related to the synaptic 
plasticity of glutamatergic neurons, since the blockade of 
NMDA receptors reduces the effects of tDCS22,23. TDCS 
has also been shown to reduce the local concentration 
of gamma aminobutyric acid (GABA), which may also 
impact glutamatergic plasticity given the close relationship 
between these two neurotransmitters [24]. TDCS can also 
influence the functional connectivity of the neural networks, 
impacting their oscillations and the synchronization 
between them25,26. There are also non-synaptic effects, since 
the presence of an electric field can cause the displacement 
of molecules involved in transmembrane ion transport, in 
the cell’s membrane structure, cytoskeleton or substance 
transport mechanisms27,28.
The classic anode-excitatory, cathode-inhibitory 
rationale is valid for the motor cortex, but cannot be 
generalized to the whole brain. For example, it was 
observed in a study with healthy volunteers that the 
expected “AeCi” (anode-excitatory / cathode-inhibitory) 
effects occurred in only 1/3 of the cases, with 40% of cases 
having excitatory effects with anode and cathode and, in 
21% of cases, the effects were reversed (anode-inhibitory 
/ cathode-excitatory)29. In addition, a greater intensity 
of electrical current for longer periods may improve the 
effectiveness of the technique in some applications30, but 
this too cannot be considered a general rule. In fact, it was 
observed that by doubling the current intensity to 2mA 
(vs 1mA) the cathode produced excitatory effects, rather 
than the expected inhibitory effects31, whereas the anodic 
stimulation at 1mA for long periods led to inhibitory 
effects32. In part, these effects can be explained by the fact 
that an increase in current intensity creates an electric field 
that penetrates more into the brain, and becomes capable of 
influencing the activity of deeper neural networks, which 
in turn impacts the biological and clinical effects33.
Another thing to be considered is that even if the 
injected currents induce depolarization or hyperpolarization 
coherent with the polarity of the electrodes, the observed 
physiological effects depend on the function of the affected 
network, which in turn can exert excitatory or inhibitory 
effects on the rest of the brain. Finally, the size of the 
electrodes and their arrangement on the scalp directly 
influence the diffusion of current and the geometry of the 
electric fields induced in the brain34,35. Thus, the variability 
of the clinical results observed with tDCS treatments may 
be directly related to anatomical differences between the 
individuals’ brains, which alter the magnitude and direction 
of the electric field resulting from the stimulation36,37.
Electroconvulsive therapy and magnetoconvulsive therapy 
(ECT and MCT)
ECT and MCT induce convulsion within a 
controlled environment in patients under general anesthesia 
via depolarization of a large number of neurons. ECT is 
performed by placing two electrodes on the head that 
discharge an electric current of low duration and high 
intensity38, while the MCT applies magnetic pulses that 
depolarize the neurons of the affected region39. The 
higher focality of the electric fields induced by MCT 
is possibly related to a lower impairment of cognitive 
functions, such as spatial disorientation and memory loss, 
than the convulsions induced by ECT, while maintaining 
the therapeutic capacity of the technique40. Nevertheless, 
ECT has a history of more than 80 years of application 
in psychiatry, and is considered one of the most effective 
therapies for mood disorders, while MCT is still a treatment 
under investigation38.
The mechanisms by which convulsive therapy work 
are still poorly understood and most of the evidence comes 
from studies of ECT in depression41. The inflammation 
theory is promising, since we have observed a decrease in 
inflammatory cytokines in depressed patients after ECT42,43. 
Inflammation activates the kinurenin pathway, leading to 
oxidative stress and serotonin depletion44, thus a marked 
reduction in inflammation could decrease depressive 
symptoms45. Other lines show that ECT increases levels 
of BDNF46, hippocampal and amygdala volume47,48 and 
functional connectivity of the hippocampus49.
STIMULATION PARAMETERS
Transcranial Magnetic Stimulation (TMS)
TMS can produce different effects and its 
applicability differs depending on the region of the brain 
being stimulated, whether this region is engaged in some 
activity or not, and the frequency, intensity and cycle of 
the generated magnetic pulses. In general, single-pulse and 
paired-pulse TMS are used to investigate brain functioning, 
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while rTMS is used to induce changes in brain activity that 
extend beyond the stimulation period50.
The combination of single-pulse and paired-pulse 
TMS with EMG measurements makes it possible for 
us to investigate various processes of the motor cortex, 
such as excitability, plasticity, cortical connectivity, as 
well as interactions between excitatory and inhibitory 
cortical processes51. In addition, it is also a valuable tool 
for understanding the pathological processes related to 
neurological and psychiatric disorders such as Parkinson’s 
disease, Alzheimer’s disease, schizophrenia, obsessive 
compulsive disorder, major depressive disorder and bipolar 
disorder52.
RTMS is used as a therapeutic tool for inducing 
long-term excitatory or inhibitory effects in brain circuits, 
with applicability to treat neurological and psychiatric 
disorders characterized by dysfunction in specific neural 
networks. This modulation of cortical activity is mainly 
dependent on stimulation frequency, with low frequencies 
(≤1 Hz) associated with an inhibitory effect to motor 
cortex excitability53, and high frequencies (5-20 Hz) 
associated with increased cortical excitability54,55. Recently, 
another rTMS protocol was approved by the Federal 
Drug Administration (FDA) called theta burst stimulation 
(TBS). The TBS is named after using a low-intensity, 
50 Hz pulse train repeated every 200 ms (5 Hz)56, which 
mimics the endogenous theta (4-7 Hz) waves of the brain, 
and resembles the experimental models of inducing LTP 
and LTD of synaptic activity. Different patterns of TBS 
stimulation (continuous or intermittent) produce opposite 
effects on the stimulated motor cortex56. Intermittent TBS 
(iTBS) applies 600 pulses in three minutes, and increases 
motor cortical excitability similar to LTP, while continuous 
TBS (cTBS) reduces it, similar to LTD56.
A rTMS protocol involves the selection of these 
stimulation parameters, and should take into account the 
desired physiological effect and existing evidence for rTMS 
treatment of the patient’s condition57. A rTMS session 
usually involves application of 600 to 3000 pulses.
• Stimulation frequency:
Typical patterns for a high frequency rTMS involve 
a 5 second 10 Hz pulse train, a 20 to 40 seconds pause 
between pulse trains, with a total of 1200 to 3000 pulses 
emitted over a time interval of 15 to 45 minutes. This 
pause between trains is recommended, and its time must 
conform to the most current safety guidelines58. Low 
frequency rTMS does not require pause between trains, so a 
stimulation session consists of a 1 Hz pulse sequence with 
600 to 1500 pulses emitted in a relatively shorter interval.
TBS consists of the application of a 5 Hz train of 3 
to 5 50 Hz pulses. For iTBS, of excitatory effect, 2 second 
interval of 50 Hz pulses followed by an 8 second pause 
is usually applied, with a session of 1200 pulses lasting 
less than 8 minutes. The cTBS, of inhibitory effect, does 
not use pauses, with a session of 1200 pulses emitted in 
approximately 3 minutes56.
There are also other interventions that combine 
protocols of high and low frequencies in the same session. 
One method is called a bilateral rTMS, which applies 
high frequency stimulation on one side of the brain 
simultaneously, or more often sequentially, to the low 
frequency stimulation on the other side. Another method is 
called priming, when a specific protocol is applied in one 
particular brain region before another, in order to intensify 
the effects of the second protocol59.
• Resting motor threshold (RMT):
The resting motor threshold is classically defined 
as the smallest percentage of the maximum field strength 
required to generate a MEP of 50 μV or more in at least 
5 of 10 attempts. The RMT is usually determined by 
stimulating the region of the motor cortex that controls 
hand movements and performing EMG on one of the 
small muscles of the hand. It is important to determine the 
RMT in order to have a field strength intensity that causes 
depolarization of the motor cortex, thus extrapolating this 
stimulation effect to other cortical regions. Usually, rTMS 
protocols use intensities of 100 to 120% of the RMT, while 
TBS protocols use intensities of 80 to 100%.
• Field coil:
The shape of the coil is related to the shape of the 
generated magnetic field, which in turn determines the 
intensity, precision and depth of the stimulation. The most 
commonly used field coil is the 8-shaped coil, which creates 
a heavily focused magnetic field in the center. Also used 
are H-shaped and double-cone coils.
• Coil positioning:
The cortical target of stimulation is a crucial 
parameter for the therapeutic effect of TMS, since 
the desired physiological effects depend on properly 
stimulating the stipulated areas. When determining the 
region to be stimulated, it is important to position the coil 
correctly so that the generated field reaches that region. 
The gold standard for targeting is through neuronavigation, 
which consists of using magnetic resonance imaging of the 
patient’s brain integrated into a spatial positioning system 
and a group of sensors by software that indicates the 
relative position of the sensors to the brain. In the absence 
of neuronavigation, anatomical methods can be used. These 
methods use cranial reference points to estimate the target. 
The most widely used of these is the international 10-20 
system for electroencephalography (EEG).
Transcranial Current Stimulation (tDCS)
The main parameters of tDCS are the intensity 
of the electrical current administered, the duration of 
the stimulation session, the size and positioning of the 
electrodes on the scalp, the number of sessions and the 
283
Rev Med (São Paulo). 2019 July-Aug;98(4):279-89.
interval between sessions60. The currents applied are 
between 0.5 and 2 mA; sessions last from 9 to 30 minutes; 
the size of the electrodes ranges from 3.5 to 100 cm², the 
most common being 25 and 35 cm². The positioning of the 
electrodes has to be done in order to direct the current to 
the target region, with the international 10-20 EEG system 
being the most common reference for this positioning. 
Effects resulting from a single stimulation session usually 
last a few minutes, while multiple sessions prolong 
these effects for up to weeks61, and are used clinically. 
In the scope of the research, different configurations of 
these parameters are being explored in order to expand 
our understanding of the technique and also to find new 
configurations that can be effective as a form of treatment.
Electroconvulsive therapy and Magnetoconvulsive therapy 
(ECT and MCT)
ECT parameters are the positioning of the electrodes, 
the intensity and width of the electrical pulses. The most 
common assemblies are bitemporal (BT), bifrontal (BF) and 
unilateral right (ULR). The intensity is measured according 
to the lowest intensity that produces a seizure, called a 
seizure threshold (ST). Bilateral treatments (BT and BF) 
usually use 1.5 to 2 times ST, while ULR applies 5 to 8 
times ST38. A meta-analysis62 compared the three positions 
and found similar efficacy among them, but with different 
effects on cognitive functions. BF and ULR ECT are 
considered first-line treatments, and BT is recommended 
as a second-line treatment due to a higher index of short-
term adverse effects on cognition38. Brief pulses (BP, 0.5 
to 1.5 ms duration) or ultra short pulses (USP, duration less 
than 0.5 ms) are usually used. USP may be associated with 
lower cognitive impairment, specifically memory loss63, but 
may also have a slower pace of improvement and require 
more sessions than BP64. MCT parameters are still under 
investigation. Most studies position the coil at the apex 
(equivalent to Cz in the 10-20 EEG), apply a stimulation 
frequency of 100 Hz, pulse width of 0.2 to 0.4 ms, and 
stimulation of 10 seconds. Treatment is usually done 2 to 
3 times a week, for a total of 12 sessions38.
CONTRAINDICATIONS, ADVERSE EFFECTS AND 
SAFETY
The contraindications for rTMS and tDCS are 
very similar, and include presence of ferromagnetic parts 
or electronic devices near the stimulation area that can be 
heated or damaged by induced electric currents. 
RTMS may in some cases cause seizures. 
However, the number of occurrences reported is very small 
(<0.1%), and none of them reported irreversible damage or 
death58. The risk of seizure is associated with higher RMT, 
higher stimulation frequencies, longer pulse train duration 
and shorter interval between trains58. The experience gained 
from clinical trials allows the development of increasingly 
safe protocols in order to establish the limits for the different 
stimulation parameters. For patients with a previous history 
of seizures, low frequency rTMS is recommended, which 
is not associated with a risk of seizures and may even have 
protective effects66. Other adverse effects of rTMS include 
headache and discomfort at the stimulation site58. Adverse 
effects of ECTS include tingling, paresthesia, redness and 
discomfort at the site of stimulation.
There are no absolute contraindications for ECT 
and MCT. The following conditions are associated with 
higher risks: brain injury, elevated intracranial pressure, 
recent myocardial infarction, recent cerebral haemorrhage, 
presence of aneurysm, pheochromocytoma, and class 4 or 
5 of anesthesia risk38. The most common adverse effects 
are short-term cognitive impairments, such as spatial 
disorientation, retrograde and anterograde amnesia, which 
may last from weeks to a few months, and symptoms that 
appear during treatment such as headache, muscle aches, 
and nausea.
CLINICAL EVIDENCE
Major Depressive Disorder (MDD)
Transcranial Magnetic Stimulation (TMS)
According to the Canadian Network for Mood 
and Anxiety Treatments (CANMAT), rTMS is a first-line 
treatment for patients who have not had improvement after 
at least one drug treatment. The recommended stimulation 
parameters are 110 to 120% of the RMT for high and low 
frequency rTMS and 70 to 80% of the RMT for TBS, 5 
times a week, for a total of 20 to 30 sessions or less if 
clinical response is obtained68. The stimulated region is 
the left dorsolateral prefrontal cortex (DLPFC) in the case 
of high frequency rTMS, or the right DLPFC in the case 
of low frequency rTMS, both of which are considered 
first-line protocols. There is a suggestion that patients who 
do not respond to treatment with low-frequency rTMS in 
the right DLPFC can respond to high-frequency therapy 
in the left DLPFC, and vice versa. Thus, a second-line 
recommendation is to switch non-responsive patients to 
the other treatment protocol68.
The US Food and Drug Administration (FDA) 
also approved a treatment protocol for MDD using rTMS 
that involves stimulating the left DLPFC for 37.5 minutes 
with 10 Hz pulses (a total of 3000 pulses per session) to 
120 % of the RMT, 5 days per week for a period of 4 to 
6 weeks69. Although it is a standard protocol for MDD 
treatment of drug-resistant patients, when compared 
to electroconvulsive therapy (ECT), it has been shown 
inferior, especially in psychotic patients70. In addition, 
rTMS was shown to be ineffective in patients resistant to 
ECT, indicating that treatment should not be used if ECT 
was not successful.
Recently, the FDA also approved a TBS protocol 
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for the treatment of MDD following a clinical trial that 
indicated non-inferiority of TBS over the standard high-
frequency rTMS protocol71. The clinical trial used iTBS 
applied to left DLPFC with intensity of 120% of the RMT, 
5 Hz pulse train consisting of 3 50 Hz pulses, 2 seconds 
active and 8 seconds inactive, with a total of 600 pulses 
emitted in 3 minutes and 9 seconds, 5 days a week for four 
weeks. The main advantage of this new 3-minute protocol 
over the 37.5-minute pattern is the shorter stimulation time. 
Although the number of pulses is very different between the 
two treatments, the response to treatment by iTBS is similar 
to that of the standard protocol. In addition, a positive 
result of the study is that the patients evaluated had drug 
resistant MDD and did not respond, on average, to one or 
two previous pharmacological treatments71.
Transcranial Current Stimulation (tDCS)
CANMAT considers tDCS a third line treatment 
for MDD. This is due to heterogeneous methodologies 
and inconsistent meta-analysis results. Future studies are 
needed to establish optimal stimulation parameters for 
tDCS as monotherapy or in combined therapies68.
The role of tDCS as a combined therapy or as a 
substitute for antidepressants has been investigated in 
two large clinical trials. Sertraline vs. Electric Current 
Therapy for Treating Depression Clinical Study (SELECT-
TDCS)72 recruited 120 patients who had not previously 
used antidepressants, with moderate to severe depression, 
and randomized them into four groups: sham tDCS and 
placebo pill, sham tDCS and sertraline, active tDCS 
and placebo pill, and active tDCS and sertraline. The 
stimulation parameters were: 2 mA, 30 minutes per day 
for 2 weeks, followed by two sessions of tDCS every two 
weeks until the sixth week. Sertraline dose was 50 mg / 
day. The main conclusions were: 1) combined therapy was 
significantly more effective than monotherapy; 2) active 
tDCS as monotherapy was more effective than placebo; 
3) tDCS was well tolerated, with few adverse effects, 
although five cases of mania / hypomania were reported 
in the combined group.
The findings that tDCS and sertraline are not 
statistically different are limited because the dose of 
sertraline was low and the study was not designed to show 
non-inferiority. The Escitalopram vs. Electric Current 
Therapy to Treat Depression Clinical Study (ELECT-
TDCS)73 was designed to demonstrate non-inferiority of 
tDCS to the maximum dosage of escitalopram (20 mg / 
day). ELECT-TDCS lasted for 10 weeks (instead of 6 weeks 
of SELECT-TDCS), and more tDCS sessions were applied 
(22 instead of 12). ELECT-TDCS failed to demonstrate 
non-inferiority of tDCS compared to escitalopram, which 
means that the stimulation was shown as not inferior to the 
administered antidepressant. Superiority analysis showed 
that escitalopram was superior to tDCS and placebo, 
whereas tDCS was superior to placebo. The stimulation 
protocol used in this study was 5 weekly stimulation 
sessions in the first 3 weeks, followed by intermittent 
sessions in the other 7 weeks; a more intense stimulation 
protocol could have been more effective, in the same 
way that early studies of rTMS involving two weeks of 
stimulation showed modest results compared to studies 
that lasted 4 to 6 weeks.
A multi-center study74 involving 130 participants 
diagnosed with MDD and randomized to receive active 
tDCS (2.5 mA for 30 minutes) or sham (0.034 mA and 
two 60-second current ramps to mimic the sensation of 
skin tingling) applied to left DLPFC , administered in 
20 sessions in a period of 4 weeks found no significant 
difference between active and placebo stimulation. In 
addition, for patients with unipolar depression, placebo 
resulted in a higher remission rate than active tDCS. This 
finding points to the possibility that the current applied by 
the sham stimulation may be biologically active, especially 
when applied during 20 sessions over 4 weeks. Another 
important consideration is regarding the ideal “dose” of 
current. The optimal current intensity for the therapeutic 
effects of tDCS is not known, and it may be that 2.5 mA 
for 30 minutes in 20 sessions exceeds this optimal “dose” 
for many participants.
Electroconvulsive therapy (ECT)
ECT is one of the most effective treatments for 
MDD. Treatment response rates reach 70%, with remission 
rates of 50% or higher, depending on the population and 
the type of stimulus used38. For example, a multicenter (n 
= 230) study reported remission rates of 55% for ULR, 
61% for BF and 64% for BT in a mixed group of patients 
with unipolar (77%) and bipolar (23%) depression75. The 
greatest predictor of non-response to ECT is resistance to 
previous treatments; in patients with degrees of resistance to 
pharmacological and psychological treatments, the rate of 
ECT response was approximately 50%, compared to 65% 
in nonresistant patients76. The relapse rate, with or without 
maintenance of treatment, is also high. A meta-analysis of 
32 studies from 1962 to 2013 that analyzed the relapse rate 
after successful treatment with ECT reported that this rate 
is higher in the 6 months posttreatment (37.7%)77. Even in 
those receiving a post-ECT maintenance treatment, relapse 
rates of approximately 50% after 1 year were observed.
Schizophrenia
Noninvasive stimulation techniques have been 
used to treat auditory hallucinations (AH) and negative 
symptoms in schizophrenia78-81. Patients with AH have 
increased blood flow in the left cerebral hemisphere, 
particularly in the upper temporal gyrus81. Thus, solutions 
that apply low frequency rTMS or cathode tDCS on this 
region have been investigated. A recent meta-analysis79 
demonstrated a significant clinical effect of low-frequency 
rTMS on the left temporoparietal region, but no large 
285
Rev Med (São Paulo). 2019 July-Aug;98(4):279-89.
clinical trial confirmed this finding. In a clinical trial of 30 
patients who underwent tDCS, anodic stimulation on TP3 
and cathodic on F3 decreased AH for up to three months 
after application78.
High-frequency rTMS has been used to treat 
negative symptoms of schizophrenia. Pulses are applied 
to the DLPFC, the brain region that exhibits reduced 
blood flow and metabolism under these conditions82, and 
although initial results are promising80, a recent clinical 
trial recruiting 156 patients with schizophrenia and 
exacerbated negative symptoms did not show superiority 
of high frequency rTMS applied to DLPFC in 105 days 
of post-treatment follow-up83. Studies with small groups 
of patients receiving tDCS suggest efficacy of an anodal 
stimulation protocol on the DLPFC and association of 
clinical improvement with increased connectivity between 
the DLPFC and left temporal gyrus78,84.
Obsessive Compulsive Disorder (OCD)
The U.S. FDA has approved deep transcranial 
magnetic stimulation (dTMS), a rTMS modality which 
targets neural networks that are deeper in the brain by 
using a more focalized coil, for treatment of OCD. The 
basis for approval was a clinical trial involving 100 patients 
which showed that dTMS targeting the dorsomedial 
prefrontal cortex (DMPFC) and the anterior cingulate 
cortex significantly improved OCD symptoms85. Moreover, 
there is growing evidence of rTMS efficacy for OCD 
targeting supplementary motor cortex and the DLPFC86,87. 
No controlled clinical trial evaluating the efficacy of tDCS 
in OCD has been finalized. A study is investigating the 
efficacy of cathodal stimulation on the motor supplemental 
area with 2 mA88. Other studies indicate promising results 
using this assembly89,90.
FUTURE PERSPECTIVES
New therapeutic targets
The DLPFC is the most common target for treatment 
of depression by noninvasive techniques. Although it is 
involved in the pathophysiology of the disease, it was 
initially targeted because it was easily accessible, and also 
because our knowledge about the other circuits involved 
in depression was limited91.
It is interesting to note that most of the evidence 
of prefrontal asymmetry and hypoactivity of DLPFC in 
depression comes from rTMS studies themselves. The most 
consistent piece of evidence is that DLPFC is involved in 
processing information other than emotions, and that, which 
are not among the main symptoms of the disease91. Thus, 
the antidepressant effects of rTMS on DLPFC may be by 
indirect mechanisms, through changes in the connectivity 
of neural networks.
A possible target for future studies of rTMS in 
depression is the DMPFC. It is a center of convergence 
of several neural networks involved in cognitive control, 
regulation of affection and self-concerning thoughts92. 
Injuries in this region cause mood disorders in more than 
80% of cases93. A meta-analysis of cerebral morphometry 
showed a reduction of gray matter in the DMPFC and the 
anterior cingulate cortex in patients with depression, while 
reporting few changes of the DLPFC94. Other areas involved 
in the pathophysiology of depression are the frontopolar 
cortex (FPC), the prefrontal ventromedial cortex (VMPFC), 
and the ventrolateral prefrontal cortex (VLPFC), which 
are hyperactive in depression and are associated with a 
symptomatic improvement when deactivated91,93. The 
drawback is that VMPFC and VLPFC are not easily 
accessible, whereas FPC is in a region where stimulation 
may be uncomfortable by causing muscle contraction of 
the face, and visual perceptions by stimulating the retina91.
Biomarkers
The use of biomarkers for noninvasive therapies 
may be useful in identifying groups of patients who have 
a greater response to rTMS when compared to other 
interventions or placebo. Two recent studies indicate 
possible predictors of response.The first study95 showed 
that patients who did not respond to rTMS treatment had 
higher anhedonia and lower connectivity of a classically 
reward-associated neural circuit, which is the tegmentum, 
striatum and part of the VMPFC, at the beginning of 
treatment. This study identified that a particular subtype 
of depression in patients, defined from syndromic and 
neuroimaging characteristics, may respond better to rTMS.
The other study96 used functional magnetic resonance 
imaging in a multicenter sample of 1188 depressed 
patients and identified four neurophysiological subtypes 
(“biotypes”) based on distinct patterns of dysfunctional 
connectivity of frontostriatal and frontolimbic networks. 
Patients of “biotype 1” were approximately three times 
more likely to benefit from rTMS treatment than patients 
from “biotypes 2 and 4”. The authors suggested that there 
is a neural signature associated with the clinical response 
of rTMS.
CONCLUSION
Noninvasive techniques, such as rTMS and tDCS, 
the most common methods, are increasingly being applied 
in clinical practice, due to the research progress in these 
areas in recent decades. The most promising results are 
of applications for treating MDD and, to a lesser extent, 
schizophrenia. Advantages include mild side effects and 
the absence of impaired contraindications. However, the 
therapeutic effects of these techniques are still modest, 
possibly due to the limited understanding of their effects 
on brain function in healthy and ill patients. The continued 
development of noninvasive techniques is crucial to 
elucidate their role in the therapeutic arsenal for treating 
psychiatric disorders.
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